Chemistry:AZD7442
AZD7442 is an intramuscular antibody cocktail developed by British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca.[1][2]
History
In 2020, researchers at Vanderbilt University Medical Center discovered particularly potent antibodies, isolated from COVID-19 patients infected with the wild strain. AZ licensed the antibodies who developed monoclonal antibody treatments from them and funded clinical trials including Provent, which enrolled 5,000 high risk individuals to assess their usefulness and continued for 6 months of follow up.[3]
The trial reported that those receiving the cocktail showed a 77% reduction in symptomatic COVID-19 and that there were no severe cases or deaths. AstraZeneca also found that the antibody cocktail "neutralizes recent emergent SARS-CoV-2 viral variants, including the Delta variant".[2] The StormChaser trial by contrast failed to meet its primary endpoint. AZD7442 was administered to 1,000 post-exposure individuals who had yet to test positive.[3]
On 20 August 2021, AstraZeneca announced the results[1][2] and that it would seek emergency use authorization.[1]
References
- ↑ 1.0 1.1 1.2 Ray, Siladitya (2021-08-21). "AstraZeneca’s Covid-19 Antibody Therapy Effective In Preventing Symptoms Among High-Risk Groups, Trial Finds" (in en). https://www.forbes.com/sites/siladityaray/2021/08/20/astrazenecas-covid-19-antibody-therapy-effective-in-preventing-symptoms-among-high-risk-groups-trial-finds/.
- ↑ 2.0 2.1 2.2 O. Goriainoff, Anthony (2021-08-20). "AstraZeneca Says AZD7442 Antibody Phase 3 Trial Met Primary Endpoint in Preventing Covid-19" (in EN-US). https://www.marketwatch.com/story/astrazeneca-says-azd7442-antibody-phase-3-trial-met-primary-endpoint-in-preventing-covid-19-271629440744.
- ↑ 3.0 3.1 Haridy, Rich (2021-08-23). "“Game-changing” antibody cocktail prevents COVID-19 in the chronically ill" (in en-US). https://newatlas.com/health-wellbeing/astrazeneca-antibody-coronavirus-phase3-trial-results/.
Template:COVID19-pandemic-stub
 |
